TABLE 2.
MIC-related pharmacokinetic parameters and antibacterial effect indices of the simulation of oral administration of ciprofloxacin (750 mg/12 h over 48 h) and moxifloxacin (400 mg/24 h over 48 h) against a clinical isolate of S. maltophilia (Sm206) and two reference strains, CIP 54.90 and CIP 60.77T
| Parameter | Mean or mean ± SD for strain: |
|||||
|---|---|---|---|---|---|---|
| Sm206 |
CIP 54.90 |
CIP 60.77T (ATCC 13637) |
||||
| Ciprofloxacin (MIC = 2 μg/ml; n = 3) | Moxifloxacin (MIC = 0.5 μg/ml; n = 3) | Ciprofloxacin (MIC = 1 μg/ml; n = 2) | Moxifloxacin (MIC = 0.25 μg/ml; n = 2) | Ciprofloxacin (MIC = 0.5 μg/ml; n = 2) | Moxifloxacin (MIC = 0.0625 μg/ml; n = 2) | |
| Doubling time (h) | 0.65 ± 0.10 | 0.59 ± 0.06 | 0.61 | 0.57 | 0.55 | 0.55 |
| Cmax/MIC at: | ||||||
| 0.90 h | 4.90 ± 0.23 | |||||
| 1 h | 1,54 ± 0.21 | 2.48 | 9.80 | 6.20 | 38.5 | |
| 24.90 h | 5.63 ± 0.46 | 12.6 | ||||
| 25 h | 1.72 ± 0.11 | 2.96 | 6.70 | 45.1 | ||
| AUC0-24/MIC (h) | 12.0 ± 0.7 | 35.1 ± 0.6 | 22.6 | 68.8 | 49.4 | 267.2 |
| AUC24-48/MIC (h) | 13.5 ± 1.1 | 38.6 ± 0.9 | 25.2 | 77.6 | 50.2 | 286.7 |
| Δlog CFU/ml at: | ||||||
| t1 | 0.32 ± 0.09 | −1.08 ± 0.17 | 0.24 | −0.15 | −0.07 | −1.24 |
| t6 | −0.42 ± 0.30 | −2.56 ± 0.33 | −0.12 | −0.81 | −0.49 | −1.77 |
| t12 | 1.79 ± 0.22 | −1.37 ± 0.89 | 1.35 | −1.03 | −0.30 | −1.17 |
| t24 | 1.66 ± 0.12 | 2.08 ± 0.02 | 1.53 | 2.17 | 2.93 | −0.80 |
| t25 | 1.65 ± 0.19 | 2.13 ± 0.03 | 1.21 | 2.42 | 2.64 | −0.73 |
| t48 | 1.81 ± 0.13 | 2.08 ± 0.13 | 2.34 | 2.97 | 2.81 | 1.79 |
| AUBC0-48 (h × log CFU/ml) | 401.3 ± 3.7 | 378.7 ± 13.8 | 371.8 | 343.2 | 342.3 | 295.2 |
| ABBC0-48 (h × log CFU/ml) | 40.4 ± 3.7 | 72.9 ± 13.8 | 81.5 | 101.8 | 101.1 | 144.7 |